Read by QxMD icon Read

Journal of Thrombosis and Haemostasis: JTH

D Wang, Z-Y Luo, Z-P Yu, L-X Liu, C Chen, W-K Meng, Q-P Yu, F-X Pei, Z-K Zhou, W-N Zeng
Essentials Perioperative blood loss and inflammatory response can significantly affect recovery after surgery. We studied the effects of multiple-dose oral tranexamic acid on blood loss and inflammatory response. A postoperative four-dose regimen brought about maximum reduction in postoperative blood loss. A postoperative four-dose regimen reduced inflammatory response and promoted early rehabilitation. SUMMARY: Background Tranexamic acid (TXA) can reduce blood loss and the inflammatory response at multiple doses in total knee arthroplasty patients...
November 15, 2018: Journal of Thrombosis and Haemostasis: JTH
Carsten Horn, Claude Négrier, Uwe Kalina, Wilfried Seifert, Kenneth D Friedman
BACKGROUND: Measuring factor IX activity (FIX:C) with one-stage clotting (OSC) assays, based on the activated partial thromboplastin time (aPTT), is the current mainstay of diagnostic techniques for hemophilia B. Assessing the performance of new recombinant FIX (rFIX) products in OSC assays is essential as aPTT reagents from different manufacturers yield different potency estimates for rFIX. OBJECTIVES: To evaluate the extent to which choice of reagent composition influences rFIX potency measurements of recombinant FIX-albumin fusion protein (rIX-FP, IDELVION® ) activity in OSC assays...
November 12, 2018: Journal of Thrombosis and Haemostasis: JTH
L G Poole, A Pant, K S Baker, A K Kopec, H M Cline-Fedewa, S E Iismaa, M J Flick, J P Luyendyk
INTRODUCTION: Intravascular fibrin clots and extravascular fibrin deposits are often implicated in the progression of liver fibrosis. However, evidence supporting a pathological role of fibrin in hepatic fibrosis is indirect and based largely on studies using anticoagulant drugs that inhibit activation of the coagulation protease thrombin, which has other downstream targets that promote fibrosis. Therefore, the goal of this study was to determine the precise role of fibrin deposits in experimental hepatic fibrosis...
November 11, 2018: Journal of Thrombosis and Haemostasis: JTH
Ton Lisman
Both basic and applied studies dealing with aspects of hemostasis in liver diseases have spurred significant controversy over the last two decades[1]. Clinically, we have learnt that patients with liver diseases do not necessarily have a hemostatic defect resulting in a bleeding tendency. Instead, these patients appear in hemostatic balance due to a decline in both pro- and antihemostatic pathways, and may experience both bleeding and thrombotic complications when this reset hemostatic balance is offset[2]...
November 9, 2018: Journal of Thrombosis and Haemostasis: JTH
C Arnold Spek, Cansu Tekin, Maarten F Bijlsma
Protease activated receptor 1 (PAR-1), originally identified as the thrombin receptor on platelets and vascular endothelial cells, is expressed on numerous cells throughout the body. Tumor cells, and cells in the tumor microenvironment like cancer-associated fibroblasts, macrophages, T cells and endothelial cells, are no exception and PAR-1 expression is abundant in a variety of cancer tissues [1,2]. The potential relevance of PAR-1 expression for tumor growth is underscored by observations that PAR-1 expression levels correlate with cancer progression and overall survival [1,2]...
November 9, 2018: Journal of Thrombosis and Haemostasis: JTH
Brett J Carroll, Gregory Piazza, Samuel Z Goldhaber
Sulodexide is a glycosaminoglycan extracted from porcine intestinal mucosa. The purpose of this review is to discuss sulodexide's complex pharmacologic profile and its clinical applications for venous disease. Sulodexide has wide-ranging biologic effects on the vascular system, including anti-thrombotic, pro-fibrinolytic, anti-inflammatory, endothelial protective, and vasoregulatory properties. Sulodexide has emerged as a potential therapeutic option for management of chronic venous insufficiency, including venous ulceration, and prevention of recurrent venous thromboembolism, with a low rate of major bleeding complications...
November 5, 2018: Journal of Thrombosis and Haemostasis: JTH
S De Maat, C C Clark, M Boertien, N Parr, W Sanrattana, Z L M Hofman, C Maas
BACKGROUND: The contact activation system and innate immune system are interlinked in inflammatory pathology. Plasma kallikrein (PKa) is held responsible for the step-wise processing of factor XII (FXII). A first cleavage activates FXII (into FXIIa); subsequent cleavages truncate it. This truncation eliminates its surface-binding domains, which negatively regulates surface-dependent coagulation. OBJECTIVES: To investigate the influence of FXII truncation on its activation and downstream kallikrein-kinin system activation...
November 5, 2018: Journal of Thrombosis and Haemostasis: JTH
Keigo Akuta, Hirokazu Kashiwagi, Toshiaki Yujiri, Nobuko Nishiura, Yoichiro Morikawa, Hisashi Kato, Shigenori Honda, Yuzuru Kanakura, Yoshiaki Tomiyama
BACKGROUND: Acquired Glanzmann thrombasthenia (aGT) is a bleeding disorder generally caused by function-blocking anti-αIIbβ3 autoantibodies. AIM: We characterize an unusual case of aGT caused by marked reduction of surface αIIbβ3 with non function-blocking anti-αIIbβ3 antibodies (Abs). METHODS: A 72 year-old male suffering from immune thrombocytopenia since his 50's showed exacerbation of bleeding symptom despite of mild thrombocytopenia...
November 2, 2018: Journal of Thrombosis and Haemostasis: JTH
J W Weisel, R I Litvinov
No abstract text is available yet for this article.
October 31, 2018: Journal of Thrombosis and Haemostasis: JTH
Mike Makris, Albert Farrugia
We read with interest the paper by Azengruber and colleagues recently published in the journal. The authors reported significant variation among the different recombinant concentrates in terms of content of soluble protein aggregates and subvisible particles. This could be important in explaining the differential immunogenicity, in terms of inhibitor development, among recombinant concentrates. We were, however, disappointed that the authors do not name the nine brands of recombinant FVIII concentrates they studied...
October 30, 2018: Journal of Thrombosis and Haemostasis: JTH
Maaike Schillemans, Ellie Karampini, Marije Kat, Ruben Bierings
The blood vessel wall minimizes blood loss and prevents or overcomes infections in the event of vascular trauma with a number of self-healing properties. Endothelial cells pre-package a cocktail of hemostatic, inflammatory and angiogenic mediators in their unique secretory organelles, the Weibel-Palade bodies (WPBs)[1], which can be immediately released on demand. Secretion of their content into the vascular lumen through a process called exocytosis enables the endothelium to actively participate in the arrest of bleeding and to slow down and direct leukocytes to areas of inflammation...
October 30, 2018: Journal of Thrombosis and Haemostasis: JTH
A Shenoy, J G Stine, N M Intagliata
We read with interest the article by Barba and colleagues entitled "Venous thromboembolism in patients with liver diseases."(1) This study examines a national inpatient registry of hospital admissions to determine risks of patients with a diagnosis of various severities of "liver disease" and development of in-hospital venous thromboembolism (VTE). The authors conclude that the presence of "mild liver disease" is a risk factor for VTE, whereas the presence of "moderate to severe" liver disease is not a risk factor for the development of VTE, but instead may actually be protective...
October 26, 2018: Journal of Thrombosis and Haemostasis: JTH
F Peyvandi, A Mamaev, J-D Wang, O Stasyshyn, M Timofeeva, N Curry, A R Cid, T T Yee, K Kavakli, G Castaman, A Sytkowski
BACKGROUND: Recombinant von Willebrand factor (rVWF) has demonstrated efficacy for on-demand treatment of bleeding in severe von Willebrand disease (VWD), warranting evaluation in the surgical setting. OBJECTIVES: This study (NCT02283268) evaluated the hemostatic efficacy/safety profile of rVWF, with/without recombinant factor VIII (rFVIII), in patients with severe VWD undergoing surgery. PATIENTS/METHODS: Patients received rVWF 40-60 IU/kg, VWF ristocetin cofactor activity was measured 12-24 hours before surgery...
October 25, 2018: Journal of Thrombosis and Haemostasis: JTH
Johan Boender, Jeroen Eikenboom, Johanna G van der Bom, Karina Meijer, Joke de Meris, Karin Fijnvandraat, Marjon H Cnossen, Britta A P Laros-van Gorkom, Waander L van Heerde, Evelien P Mauser-Bunschoten, Moniek P M de Maat, Frank W G Leebeek
BACKGROUND: Measuring the ability of von Willebrand factor (VWF) to bind to platelets is crucial for the diagnosis and classification of von Willebrand disease (VWD). Several assays that measure this VWF activity using different principles are available, but the clinical relevance of different assay principles is unclear. OBJECTIVE: To compare the four most widely used VWF activity assays in a large VWD patient population. METHODS: We measured VWF:RCo (ristocetin to activate VWF + whole platelets), VWF:GPIbR (ristocetin + platelet glycoprotein Ib receptor (GPIb) fragments), VWF:GPIbM (gain-of-function GPIb fragments that bind VWF spontaneously without ristocetin), and VWF:Ab (monoclonal antibody directed against the GPIb binding epitope of VWF to mimic platelets) - in 661 VWD patients from the nationwide "Willebrand in the Netherlands" (WiN) Study...
October 25, 2018: Journal of Thrombosis and Haemostasis: JTH
Edward T Van Matre, Paul M Reynolds, Robert MacLaren, Scott W Mueller, Garth C Wright, Marc Moss, Ellen L Burnham, P Michael Ho, R William Vandivier, Tyree H Kiser
BACKGROUND: Critically ill patients with cancer are at increased risk of venous thromboembolism (VTE) from physical and cellular factors, requiring pharmacologic prophylaxis to reduce the risk of VTE. OBJECTIVES: To assess whether low-molecular-weight heparin (LMWH) prophylaxis reduces in-hospital rates of VTE or improves clinical outcomes compared to unfractionated heparin (UFH) prophylaxis in critically ill patients with cancer. METHODS: Propensity matched comparative effectiveness cohort Premier Database study...
October 22, 2018: Journal of Thrombosis and Haemostasis: JTH
M J Whitley, D M Henke, A Ghazi, M Nieman, Michelle Stoller, L M Simon, E Chen, J Vesci, M Holinstat, S E McKenzie, C A Shaw, L C Edelstein, Paul F Bray
BACKGROUND: F2RL3 encodes protease-activated receptor 4 (PAR4) and harbors an A/G SNP (rs773902) with racially dimorphic allelic frequencies. This SNP mediates an alanine to threonine substitution at residue 120 that alters platelet PAR4 activation by the artificial PAR4-activation peptide, AYPGKF. OBJECTIVES: We determined the functional effect of rs773902 on stimulation by a physiological agonist, thrombin, and on antiplatelet antagonist activity. METHODS: Healthy human donors were screened and genotyped for rs773902...
October 22, 2018: Journal of Thrombosis and Haemostasis: JTH
Andrea Artoni, Alessandra Bassotti, Maria Abbattista, Barbara Marinelli, Anna Lecchi, Francesca Gianniello, Marigrazia Clerici, Paolo Bucciarelli, Silvia La Marca, Flora Peyvandi, Ida Martinelli
BACKGROUND: Ehlers-Danlos Syndrome (EDS) includes a heterogeneous group of connective tissue disorders affecting skin, bones, vessels and other organs. Patients with EDS have an increased risk of bleeding, but a comprehensive study of hemostasis in EDS patients is lacking. OBJECTIVE: We investigated the bleeding tendency of a cohort of patients with EDS using the Bleeding Assessment Tool of the International Society of Thrombosis and Hemostasis, the bleeding severity score (BSS)...
October 12, 2018: Journal of Thrombosis and Haemostasis: JTH
M Makris, J Oldenburg, E P Mauser-Bunschoten, K Peerlinck, G Castaman, K Fijnvandraat
No abstract text is available yet for this article.
October 10, 2018: Journal of Thrombosis and Haemostasis: JTH
S G Fronas, H S Wik, A Dahm, C T Jørgensen, J Gleditsch, N Raouf, F A Klok, W Ghanima
BACKGROUND: Several strategies for safe exclusion of deep vein thrombosis (DVT) while limiting the number of imaging tests have been explored. OBJECTIVES: We aimed to determine whether D-dimer could safely and efficiently exclude DVT as a stand-alone test and evaluate its performance compared to strategies that incorporate Wells score and age-adjusted D-dimer. PATIENTS/METHODS: We included consecutive outpatients referred with suspected DVT to the Emergency Department at Østfold Hospital, Norway...
October 10, 2018: Journal of Thrombosis and Haemostasis: JTH
V Taune, M Skeppholm, A Ågren, G Gryfelt, R E Malmström, A Wikman, J Van Ryn, H Wallén
Essentials A rapid test to detect thrombin inhibition by dabigatran would be valuable in acute situations. A thrombin-based trigger was applied in whole blood using rotation thromboelastometry. Effects of dabigatran were assessed in vitro and in samples from patients on dabigatran. The test produced data rapidly and was sensitive to dabigatran concentrations from 20 to 500 ng mL-1 . SUMMARY: Background Rapid determination of the anticoagulant effect of dabigatran is essential in emergency situations. Objective To study a viscoelastic test (rotational thromboelastometry [ROTEM]) for rapid determination of dabigatran effects in whole blood samples...
October 4, 2018: Journal of Thrombosis and Haemostasis: JTH
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"